Recent advances in the development of breast cancer vaccines

Andrea Milani,1 Dario Sangiolo,1 Massimo Aglietta,1,2 Giorgio Valabrega1,2 1Department of Oncology, University of Torino, Torino, Italy; 2FPO, Candiolo Cancer Institute, IRCCS, Torino, Italy Abstract: The manipulation of the immune system through the administration of a vaccine to direct an effect...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Milani A, Sangiolo D, Aglietta M, Valabrega G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fc0bb13f8715457da88c5267d1136cd6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fc0bb13f8715457da88c5267d1136cd6
record_format	dspace
spelling	oai:doaj.org-article:fc0bb13f8715457da88c5267d1136cd62021-12-02T02:09:00ZRecent advances in the development of breast cancer vaccines1179-1314https://doaj.org/article/fc0bb13f8715457da88c5267d1136cd62014-10-01T00:00:00Zhttp://www.dovepress.com/recent-advances-in-the-development-of-breast-cancer-vaccines-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314 Andrea Milani,1 Dario Sangiolo,1 Massimo Aglietta,1,2 Giorgio Valabrega1,2 1Department of Oncology, University of Torino, Torino, Italy; 2FPO, Candiolo Cancer Institute, IRCCS, Torino, Italy Abstract: The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC) cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high specificity, and long-lasting efficacy due to the establishment of immunological memory. However, BC vaccines have failed to demonstrate meaningful results in clinical trials so far. This reflects the intrinsic difficulty in breaking the complex immune-escaping mechanisms developed by cancer cells. New vaccines should be able to elicit complex immunologic response involving multiple immune effectors such as cytotoxic and antibody-secreting B cells, innate immunity effectors, and memory cells. Moreover, especially in patients with large tumor burdens and metastatic disease, combining vaccines with other strategies, such as systemic BC therapies, passive immunotherapy, or immunomodulatory agents, could increase the effectiveness of each approach. Here, we review recent advances in BC vaccines, focusing on suitable targets and innovative strategies. We report results of most recent trials investigating active immunotherapy in BC and provide possible future perspectives in this field of research. Keywords: breast cancer, cancer vaccines, cancer immunology, HER2, MUC-1, hTERTMilani ASangiolo DAglietta MValabrega GDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 159-168 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Milani A Sangiolo D Aglietta M Valabrega G Recent advances in the development of breast cancer vaccines
description	Andrea Milani,1 Dario Sangiolo,1 Massimo Aglietta,1,2 Giorgio Valabrega1,2 1Department of Oncology, University of Torino, Torino, Italy; 2FPO, Candiolo Cancer Institute, IRCCS, Torino, Italy Abstract: The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC) cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high specificity, and long-lasting efficacy due to the establishment of immunological memory. However, BC vaccines have failed to demonstrate meaningful results in clinical trials so far. This reflects the intrinsic difficulty in breaking the complex immune-escaping mechanisms developed by cancer cells. New vaccines should be able to elicit complex immunologic response involving multiple immune effectors such as cytotoxic and antibody-secreting B cells, innate immunity effectors, and memory cells. Moreover, especially in patients with large tumor burdens and metastatic disease, combining vaccines with other strategies, such as systemic BC therapies, passive immunotherapy, or immunomodulatory agents, could increase the effectiveness of each approach. Here, we review recent advances in BC vaccines, focusing on suitable targets and innovative strategies. We report results of most recent trials investigating active immunotherapy in BC and provide possible future perspectives in this field of research. Keywords: breast cancer, cancer vaccines, cancer immunology, HER2, MUC-1, hTERT
format	article
author	Milani A Sangiolo D Aglietta M Valabrega G
author_facet	Milani A Sangiolo D Aglietta M Valabrega G
author_sort	Milani A
title	Recent advances in the development of breast cancer vaccines
title_short	Recent advances in the development of breast cancer vaccines
title_full	Recent advances in the development of breast cancer vaccines
title_fullStr	Recent advances in the development of breast cancer vaccines
title_full_unstemmed	Recent advances in the development of breast cancer vaccines
title_sort	recent advances in the development of breast cancer vaccines
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/fc0bb13f8715457da88c5267d1136cd6
work_keys_str_mv	AT milania recentadvancesinthedevelopmentofbreastcancervaccines AT sangiolod recentadvancesinthedevelopmentofbreastcancervaccines AT agliettam recentadvancesinthedevelopmentofbreastcancervaccines AT valabregag recentadvancesinthedevelopmentofbreastcancervaccines
_version_	1718402690675900416

Recent advances in the development of breast cancer vaccines

Ejemplares similares